Recce PharmaceuticalsASX:RCE -1.32%31 3-Year RORE % is 19.03 as of Dec. 2025. GuruFocus rates ASX:RCE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,294 Biotechnology companies, Recce Pharmaceuticals ranks better than 79.83% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Recce Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2025 was 19.03%.
The industry rank for Recce Pharmaceuticals's 3-Year RORE % or its related term are showing as below:
ASX:RCE's 3-Year RORE % is ranked better than 79.83% of 1294
companies
in the Biotechnology industry
Industry Median: -11.54
vs ASX:RCE: 19.03
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Recce Pharmaceuticals 3-Year RORE % Related Terms
Recce Pharmaceuticals 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Recce Pharmaceuticals's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RCE vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Recce Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Recce Pharmaceuticals (ASX:RCE) has a 3-Year RORE % of 19.03 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Recce Pharmaceuticals and its competitors. According to the industry distribution chart, Recce Pharmaceuticals ranks #261 out of 1294 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Recce Pharmaceuticals' 3-Year RORE % too high?
Recce Pharmaceuticals' current 3-Year RORE % is 19.03. Based on the distribution chart, Recce Pharmaceuticals ranks #261 out of 1294 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Recce Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #261 out of 1294 companies for 3-Year RORE %. This places Recce Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current 3-Year RORE % is 19.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current 3-Year RORE % of 19.03. The current 3-Year RORE % is 19.03. Recce Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current 3-Year RORE % is 19.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
31GF Score
Get the complete analysis for ASX:RCE
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RCE has been successfully added to your 
